# Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine

> **NCT01667341** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genocea Biosciences, Inc.** · enrollment: 143 (actual)

## Conditions studied

- Genital Herpes Simplex Type 2

## Interventions

- **BIOLOGICAL:** GEN-003 with Matrix M-2
- **BIOLOGICAL:** GEN-003
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01667341
- **Lead sponsor:** Genocea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-05-09
- **Final completion:** 2014-05-09
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2018-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01667341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01667341, "Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01667341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*